Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
The antibody was designed and developed at Abzena’s Cambridge, UK,
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Subscribe To Our Newsletter & Stay Updated